- Language: English
- 1064 Pages
- Published: July 2013
- Region: Global
Summary: Insight Pharmaceuticals LLC Mar 12
- Published: March 2012
- Standard & Poors
The ratings on Langhorne, Pa.-based Insight Pharmaceuticals LLC (Insight) reflect Standard & Poor's Ratings Services' opinion that the company's financial risk profile will remain "highly leveraged" (as our criteria define the term) as a result of its high debt burden relative to its size, and its aggressive financial policy. We believe Insight will maintain leverage consistent with ratios indicative of our highly leveraged financial profile over the next year. We expect the company will continue to maintain a "weak" business risk profile, based on Insight's continuing narrow business focus within the over-the-counter (OTC) consumer products segment, and ongoing lack of international diversity in its product lines. We believe Insight maintains a highly leveraged capital structure. Specifically, we estimate the pro...
Companies mentioned in this report are: Insight Pharmaceuticals LLC
Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.
This product consists of a Summary Analysis: Bi-annual (at least). An abbreviated analysis containing Standard & Poor's issuer credit ratings as of the time the article was published. The analysis includes a rating rationale - the basis on which the rating was assigned - and an outlook section if the issuer is not on CreditWatch. Financial statistics are not included.
SHOW LESS READ MORE >
Insight Pharmaceuticals LLC